SiCare Bio
SiCare Bio offers a nano‑silica drug‑delivery platform for precise, sustained release of therapeutics.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
SiCare Bio offers a nano‑silica drug‑delivery platform for precise, sustained release of therapeutics.
OphthalmologyOncologyImmunologyContraceptionNeurology
Technology Platform
Nanoporous silicon dioxide (nPSi) particles engineered for high drug loading, programmable degradation, and targeted or extended‑release delivery of therapeutic payloads.
Opportunities
Growing demand for programmable nano‑delivery systems and the ability to partner with pharma companies across multiple therapeutic areas.
Risk Factors
Regulatory uncertainty for novel silicon‑based excipients and challenges in scaling precision manufacturing.
Competitive Landscape
Competes with polymeric and lipid nanoparticle platforms; differentiation stems from silicon‑based particles offering unique biodegradability and tunable release profiles.